Incidence and impact of organ dysfunctions associated with sepsis

被引:109
作者
Guidet, B
Aegerter, P
Gauzit, R
Meshaka, P
Dreyfuss, D
机构
[1] Hop St Antoine, Serv Reanimat Med, CUB Rea, F-75012 Paris, France
[2] Hop Ambroise Pare, Paris, France
[3] Hop Jean Verdier, Serv Reanimat, Bondy, France
[4] Lab Eli Lilly, Suresnes, France
[5] Hop Louis Mourier, Serv Reanimat Med, F-92701 Colombes, France
关键词
epidemiology; infection; intensive care; organ failure; scoring systems; severe sepsis;
D O I
10.1378/chest.127.3.942
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To study the incidence and severity of organ dysfunction associated with sepsis. Design: Comprehensive review of prospectively collected data from intensive care patients hospitalized between 1997 and 2001. Setting: Thirty-five ICUs in nonuniversity and university hospitals located in the Paris area. Patients: All patients hospitalized in the ICU for > 24 h meeting the criteria for severe sepsis (SS), either with only one organ dysfunction present during the ICU stay (SS1; n = 5,675) or with at least two organ dysfunction present during the ICU stay (SS2; n = 12,598), were compared to all other patients hospitalized for > 24 h in the ICU over the same time period (n = 47,637). Interventions: None. Measurements and main results: We collected information on demographic characteristics, type of admission, underlying disease, organ dysfunction, organ support, McCabe and Charlson-Deyo scores, simplified acute physiology score 11, length of stay, and outcome. The incidence of SS was 27.7% (8.6% for SS1 and 19.1 for SS2). Compared with non-SS patients, those with SS were significantly older, were more frequently men, required organ support more frequently, had higher severity scores, and stayed longer in the ICU and hospital. Respiratory and cardiovascular dysfunction and fungal infection were strong independent risk factors for death in SS patients, with 5.64-fold, 4.35-fold, and 2.0-fold increased risks, respectively. SS2 is significantly different from SS1: older age, more surgical stays and admission from external transfer, greater number of organ supports, site of infection (less pulmonary and urinary tract infections, and more abdominal and cardiovascular infections), type of bacteria (more methicillin-resistant Staphylococcus aureus, Pseudomonas, and fungus), ICU length of stay (20.4 d vs 11.6 d), hospital length of stay (33 d vs 27.9 d), ICU mortality (42.7% vs 5.5%), and hospital mortality (49% vs 11.3%). Conclusions: Our study identifies a subgroup of patients with an ICU stay > 24 h and SS with at least two organ dysfunctions. This group of patients requires special attention since their ICU mortality is > 40% and they occupy, almost 40% of all ICU beds.
引用
收藏
页码:942 / 951
页数:10
相关论文
共 36 条
[1]  
Aegerter P, 1998, REV EPIDEMIOL SANTE, V46, P226
[2]   Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study [J].
Alberti, C ;
Brun-Buisson, C ;
Burchardi, H ;
Martin, C ;
Goodman, S ;
Artigas, A ;
Sicignano, A ;
Palazzo, M ;
Moreno, R ;
Boulmé, R ;
Lepage, E ;
Le Gall, JR .
INTENSIVE CARE MEDICINE, 2002, 28 (02) :108-121
[3]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[4]   Current epidemiology of septic shock - The CUB-Rea network [J].
Annane, D ;
Aegerter, P ;
Jars-Guincestre, MC ;
Guidet, B .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (02) :165-172
[5]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[6]   INCIDENCE, RISK-FACTORS, AND OUTCOME OF SEVERE SEPSIS AND SEPTIC SHOCK IN ADULTS - A MULTICENTER PROSPECTIVE-STUDY IN INTENSIVE-CARE UNITS [J].
BRUNBUISSON, C ;
DOYON, F ;
CARLET, J ;
DELLAMONICA, P ;
GOUIN, F ;
LEPOUTRE, A ;
MERCIER, JC ;
OFFENSTADT, G ;
REGNIER, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (12) :968-974
[7]   Bacteremia and severe sepsis in adults: A multicenter prospective survey in ICUs and wards of 24 hospitals [J].
BrunBuisson, C ;
Doyon, F ;
Carlet, J ;
Bedock, B ;
Annonay, CH ;
Valente, E ;
Lescale, O ;
Misset, B ;
Charbonneau, P ;
Vergnaud, M ;
Cohen, R ;
Coloignier, M ;
Frances, JL ;
Combes, A ;
Duval, O ;
Dellamonica, P ;
Descamps, JM ;
Domart, Y ;
Galiacy, JL ;
Gouin, F ;
Guivarch, G ;
Hennequin, C ;
Krajevitch, A ;
Delmas, P ;
Holzapfel, L ;
Lepeu, G ;
Loirat, P ;
Thaler, F ;
Knani, L ;
Mercier, JC ;
Mouton, Y ;
Libbrecht, E ;
Offenstadt, G ;
Pinaud, M ;
Pinsart, M ;
Girou, E ;
Portier, H ;
Grappin, M ;
Rebeix, MT ;
Regnier, B ;
Gachot, B ;
Ricome, JL ;
Sollet, JP ;
Mentec, H ;
Tempelhoff, G ;
Beuret, P ;
Lepoutre, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (03) :617-624
[8]   New strategies for clinical trials in patients with sepsis and septic shock [J].
Cohen, J ;
Guyatt, G ;
Bernard, GR ;
Calandra, T ;
Cook, D ;
Elbourne, D ;
Marshall, J ;
Nunn, A ;
Opal, S .
CRITICAL CARE MEDICINE, 2001, 29 (04) :880-886
[9]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[10]   Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: Data from the PROWESS trial [J].
Dhainaut, JF ;
Laterre, PF ;
Janes, JM ;
Bernard, GR ;
Artigas, A ;
Bakker, J ;
Riess, H ;
Basson, BR ;
Charpentier, J ;
Utterback, BG ;
Vincent, JL .
INTENSIVE CARE MEDICINE, 2003, 29 (06) :894-903